{"entity":{"id":"nct06727630","kind":"trial","name":"A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma","aka":[],"tldr":"A phase 1/2 trial of PRJ1-3024 in melanoma, run by Zhuhai Yufan Biotechnologies Co., Ltd, now recruiting.","summary":"A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma is a phase 1/2 interventional study registered as NCT06727630 by Zhuhai Yufan Biotechnologies Co., Ltd, with 40 participants planned, started 2024-03-14 and due to reach its primary completion in 2025-04-30. Interventions recorded: PRJ1-3024.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06727630","url":"https://clinicaltrials.gov/study/NCT06727630"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06727630","phase":"1/2","setting":"A Phase Ib Study, Evaluating the Safety, Tolerance and Efficacy of PRJ1-3024 Capsules in China Subjects with Unresectable Local Advanced or Metastatic Melanoma","sponsor":"Zhuhai Yufan Biotechnologies Co., Ltd","enrolled":40,"outcomes":[]},"route":"/trials/nct06727630/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"company":[{"id":"zhuhai-yufan-biotechnologies","kind":"company","name":"Zhuhai Yufan Biotechnologies","route":"/companies/zhuhai-yufan-biotechnologies/"}]}}